Platelet-Rich Plasma (PRP) Therapy for Hair Loss

Platelet-rich plasma (PRP) therapy is a non-surgical hair restoration procedure that uses a concentration of the patient's own platelets to stimulate hair follicle activity. This page covers the mechanism, clinical indications, procedure steps, and decision criteria that distinguish PRP from other interventions. Understanding where PRP fits within the broader landscape of hair restoration procedures and its current regulatory standing is essential for setting accurate expectations.

Definition and Scope

PRP therapy involves extracting a small volume of blood, processing it in a centrifuge to isolate platelet-rich plasma, and injecting that plasma into the scalp at targeted zones of hair thinning or loss. The technique draws on the same autologous platelet concentration methods used in orthopedics and wound care, adapted for dermatologic application.

In the United States, PRP preparations used in hair restoration fall under the jurisdiction of the U.S. Food and Drug Administration (FDA). The FDA classifies PRP as a human cell, tissue, or cellular and tissue-based product (HCT/P) under 21 CFR Part 1271 when the plasma is processed and reinjected in the same surgical procedure. Because same-session autologous use generally meets the criteria for the "same surgical procedure" exception, standalone PRP injections for hair loss are not subject to the same premarket approval pathway required for biologics marketed as finished drug products. However, any kit or device used to prepare PRP — including centrifuge systems — is regulated as a medical device under FDA oversight. Clinicians and patients can review the regulatory context for hair restoration for a fuller breakdown of how federal and state frameworks apply to these procedures.

The American Academy of Dermatology (AAD) recognizes PRP as an adjunctive treatment option for androgenetic alopecia, and the International Society of Hair Restoration Surgery (ISHRS) has published practice standards addressing PRP protocols in the context of surgical and non-surgical hair restoration.

How It Works

PRP works through the concentrated delivery of growth factors stored in platelet alpha granules. When activated, platelets release signaling proteins including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF-1), and epidermal growth factor (EGF). These proteins collectively promote angiogenesis, extend the anagen (active growth) phase of the hair cycle, and support proliferation of dermal papilla cells — the structures that regulate follicle cycling.

A standard PRP preparation protocol involves the following steps:

1. Blood draw — typically 20–60 milliliters of peripheral venous blood
2. First centrifugation — separates red blood cells from plasma; duration and speed vary by protocol (commonly 1,500–3,000 RPM for 5–10 minutes)
3. Second centrifugation — concentrates platelets by removing platelet-poor plasma; some single-spin systems skip this step
4. Platelet activation (optional) — calcium chloride or thrombin may be added to activate release of growth factors before injection
5. Intradermal injection — PRP is injected at 1–2 centimeter intervals across the treatment zone using a fine-gauge needle or microneedling device

Platelet concentrations in prepared PRP typically range from 3 to 5 times baseline blood concentration, though this figure varies substantially based on centrifuge protocol and individual patient hematology. The absence of standardized preparation protocols across providers is a recognized limitation in the published literature, as noted in systematic reviews published in journals indexed by the U.S. National Library of Medicine / PubMed.

Common Scenarios

PRP is applied across a distinct range of clinical presentations, each with different evidence levels and patient profiles.

Androgenetic Alopecia (AGA) — The most studied application. Both male-pattern and female-pattern hair loss represent the primary indication. PRP is most frequently used in early to intermediate stages, such as Norwood Scale II–IV in men and Ludwig Scale I–II in women. At these stages, follicles remain viable and responsive to growth factor stimulation. The Norwood Scale classification and Ludwig Scale for female hair loss provide the staging frameworks clinicians use to assess candidacy.

Alopecia Areata — PRP has been studied as a treatment for patchy alopecia areata, where autoimmune follicular disruption causes circumscribed hair loss. Evidence quality is lower than for AGA, and PRP in this context is typically considered adjunctive rather than primary therapy. More detail on this condition's treatment landscape is available at alopecia areata hair restoration.

Post-Transplant Adjunct — PRP is frequently administered during or after follicular unit extraction (FUE) or follicular unit transplantation (FUT) procedures to improve graft survival rates and accelerate healing. Published data suggest adjunctive PRP may improve early follicular engraftment outcomes, though effect sizes vary across studies.

Traction and Scarring Alopecias — Evidence for PRP in traction alopecia and scarring alopecia is limited. Scarring alopecias in particular represent a contraindication or low-benefit scenario, since destroyed follicles cannot be reactivated by growth factors.

Decision Boundaries

PRP is not appropriate for all patients, and several factors define its boundary conditions.

PRP vs. Pharmacological Therapies — Minoxidil and finasteride have FDA-approved indications for androgenetic alopecia with clinical trial data spanning decades. PRP lacks an FDA-approved indication for hair loss specifically and is supported by a smaller, less uniform body of evidence. Clinicians frequently combine PRP with pharmacological agents; the rationale and evidence for that approach are covered at combining medical and surgical hair restoration.

Candidacy Factors

• Active scalp infection or dermatitis in the treatment zone is a contraindication
• Platelet disorders, anticoagulant therapy, or thrombocytopenia may disqualify patients or require hematology consultation
• Patients with advanced-stage AGA (Norwood VI–VII or Ludwig III) typically have insufficient residual follicular density for meaningful PRP response
• Systemic conditions including active cancer, blood disorders, or sepsis are recognized contraindications

Treatment Schedules — Most published protocols involve 3 monthly sessions as an induction phase, followed by maintenance injections every 3–6 months. No single protocol has achieved consensus designation as a clinical standard.

Oversight of Providers — Qualification standards for PRP administration vary by state. The hair restoration industry organizations page outlines the credentialing bodies and board certifications relevant to evaluating provider qualifications. The main hair restoration reference index provides orientation across the full scope of covered topics.

References

• U.S. Food and Drug Administration — Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), 21 CFR Part 1271
• U.S. Food and Drug Administration — Medical Devices Overview
• American Academy of Dermatology — Hair Loss: Diagnosis and Treatment
• International Society of Hair Restoration Surgery (ISHRS)
• U.S. National Library of Medicine / PubMed — PRP Hair Loss Research Index

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)